Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Study Information
Alliance Study ID: NCCTG-N0071
NCT Study ID (ClinicalTrials.gov): NCT00017121
Disease or Cancer Type: Melanoma & Skin Cancers
Alliance Study Chair: Svetomir Markovic, MD, PhD
Status: COMPLETED
Study Description
RATIONALE: Inhaling sargramostim may interfere with the growth of tumor cells and may be an effective treatment for melanoma that has spread to the lung.
PURPOSE: This phase I trial is studying the side effects and best dose of inhaled sargramostim in treating patients with melanoma that is metastatic to the lung.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information